Bradycardia Management Guidelines

Initial Assessment and Diagnostic Workup

• The American College of Cardiology recommends an initial workup for patients presenting with bradycardia, including a 12-lead ECG, comprehensive history, physical examination, and cardiac monitoring to establish correlation between symptoms and rhythm, followed by targeted laboratory testing and appropriate management based on symptom severity 1, 2
• Evaluate if heart rate is appropriate for clinical condition, typically less than 50 beats per minute when symptomatic, as recommended by the American College of Cardiology 3
• Assess for signs and symptoms of poor perfusion, such as altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or shock, as suggested by the American College of Cardiology 3, 2
• Obtain 12-lead ECG to document rhythm, rate, conduction abnormalities, and screen for structural heart disease, as recommended by the American College of Cardiology 1, 2
• Cardiac rhythm monitoring should be selected based on frequency and nature of symptoms, with options including Holter monitor, event monitor, or implantable cardiac monitor, as suggested by the American College of Cardiology 1, 2
• Laboratory testing directed toward suspected specific diagnoses, including thyroid function tests, electrolyte panel, Lyme titer, and drug levels, as recommended by the American College of Cardiology 4

Management Algorithm

• The American College of Cardiology recommends identifying and treating reversible causes of bradycardia, including medications, electrolyte abnormalities, hypothyroidism, acute myocardial ischemia or infarction, increased intracranial pressure, hypothermia, and infections 3
• Atropine is first-line therapy for acute symptomatic bradycardia, with a dose of 0.5 mg IV every 3-5 minutes to a maximum total dose of 3 mg, as recommended by the American College of Cardiology 3
• Consider IV infusion of β-adrenergic agonists, such as dopamine or epinephrine, when atropine is ineffective or contraindicated, as suggested by the American College of Cardiology 3
• Initiate transcutaneous pacing in unstable patients who don't respond to atropine, as recommended by the American College of Cardiology 3
• Consider permanent pacing for chronic symptomatic bradycardia, particularly if caused by necessary medications with no alternatives, as suggested by the American College of Cardiology 3

Management of Bradycardia with Heart Rate of 44 bpm

Initial Assessment and Management

• A heart rate of 44 bpm may be physiologic in well-conditioned athletes, during sleep, or in states of elevated parasympathetic tone—these patients are typically asymptomatic and require no treatment, as stated by the American Heart Association 5

Management of Asymptomatic Bradycardia

• The American College of Cardiology recommends that permanent pacing should NOT be performed in asymptomatic individuals with sinus bradycardia or pauses secondary to physiologically elevated parasympathetic tone, such as athletes or young healthy individuals 5
• Asymptomatic sinus node dysfunction or sleep-related bradycardia should not be treated with permanent pacing unless other pacing indications exist, according to the American Heart Association 5

Special Populations

• In spinal cord injury patients, bradycardia is often refractory to atropine due to unopposed parasympathetic stimulation, and consideration of theophylline or aminophylline may be necessary, as recommended by the American Heart Association 6
• Post-cardiac transplant patients should avoid atropine due to paradoxical effects and consider theophylline or aminophylline instead, as stated by the American College of Cardiology 6

Common Pitfalls

• The American Heart Association advises against pacing asymptomatic nocturnal bradycardia or pauses, as these are physiologic and common across all age ranges 5
• Temporary transvenous pacing should be avoided in mildly symptomatic patients, as the risks outweigh the benefits when episodes are intermittent without hemodynamic compromise, according to the American College of Cardiology 5

Management of Bradycardia

Immediate Assessment and Stabilization

• The American Heart Association recommends identifying if bradycardia is causing symptoms by assessing for signs of poor perfusion: altered mental status, ischemic chest discomfort, acute heart failure, hypotension, or shock 7
• The American Heart Association suggests evaluating oxygenation immediately as hypoxemia is a common reversible cause—look for tachypnea, intercostal retractions, suprasternal retractions, and check pulse oximetry 7
• The American College of Cardiology recommends establishing cardiac monitoring and obtaining IV access while simultaneously obtaining a 12-lead ECG to document rhythm and identify conduction abnormalities 7

Pharmacologic Management Algorithm

• The American College of Cardiology recommends administering atropine 0.5-1 mg IV bolus, repeat every 3-5 minutes to maximum total dose of 3 mg 7
• The American Heart Association suggests that atropine will be ineffective in cardiac transplant patients due to denervation—consider theophylline or aminophylline instead 8
• The American College of Cardiology recommends epinephrine infusion: 2-10 μg/min IV 7
• The American College of Cardiology recommends dopamine infusion: 2-10 μg/kg/min IV 7
• The American Heart Association recommends theophylline 100-200 mg slow IV (maximum 250 mg) or aminophylline infusion targets adenosine receptor blockade and addresses unopposed parasympathetic stimulation 8

Temporary Pacing Indications

• The American Heart Association suggests considering transcutaneous pacing for severe symptoms or hemodynamic compromise when atropine is ineffective, as a bridge to transvenous pacing or until bradycardia resolves 8
• The American College of Cardiology recommends transvenous pacing for persistent hemodynamically unstable bradycardia refractory to medical therapy until permanent pacemaker placement or resolution of reversible cause 8

Initiation of Temporary Pacing in Junctional Bradycardia

Indications for Temporary Pacing

• Temporary pacing (transcutaneous or transvenous) should be started when a patient with junctional bradycardia shows hemodynamic instability—such as altered mental status, ischemic chest discomfort, acute heart failure, systolic blood pressure < 90 mm Hg, or signs of shock—that persists despite atropine and other medical therapy. (American Heart Association / American College of Cardiology; Class IIa) [9][10]11
• No single heart‑rate cut‑off dictates pacing; the decision is based on the presence of hemodynamic compromise and related symptoms rather than a numeric rate. (AHA/ACC; Class IIa) [9][10]11
• Asymptomatic or minimally symptomatic junctional bradycardia should not be paced; this is a Class III (Harm) recommendation. (AHA/ACC) [9][10]11

Pharmacologic Management (Pre‑Pacing)

• Atropine (0.5–1 mg IV bolus, repeat every 3–5 min up to 3 mg) is the first‑line drug, but it may be ineffective or even worsen AV block when the escape rhythm is wide‑QRS (infranodal block). (AHA/ACC; Class I) – citation not required because the statement lacks a citation in the source.

Transcutaneous Pacing (TCP)

• Class IIb: TCP may be used as a bridge for patients with severe symptoms or hemodynamic compromise when atropine fails or when transvenous pacing is not immediately available. (AHA/ACC) [9][10]11
• Mechanical capture must be confirmed by pulse palpation or arterial waveform; electrical capture on the ECG alone is insufficient. (AHA; Class I) 9
• Adequate sedation/analgesia is required for conscious patients undergoing TCP. (AHA; Class I) 9

Transvenous Pacing (TVP)

• Class IIa: TVP is reasonable for persistent hemodynamically unstable junctional bradycardia refractory to medical therapy, serving as a bridge to permanent pacemaker implantation or until the rhythm resolves. (AHA/ACC) [9][10]11
• Anticipated need for prolonged temporary pacing (> hours) supports TVP use. (AHA/ACC) 11

Complication Profile of TVP

• Overall complication rates range 14–40 %, including venous thrombosis, pulmonary embolism, arrhythmias, loss of capture, cardiac perforation, and death. (AHA/ACC; Class IIa) [9][11]
• Infection risk rises when TVP is placed before a permanent pacemaker. (AHA/ACC; Class IIa) [9][11]
• The femoral venous approach carries the highest thrombosis risk, reported between 18–85 %. (AHA; Class IIa) 9

Contraindications / Situations to Avoid Pacing

• Do not pace patients with minimal or infrequent symptoms lacking hemodynamic compromise (Class III Harm). (AHA/ACC) [9][10]11
• Do not pace asymptomatic junctional bradycardia. (ACC; Class III Harm) 10
• Do not pace sleep‑related bradycardia. (ACC; Class III Harm) 10

Reassessment After Intervention

• Following any intervention (atropine, vasopressors, or pacing), reassess after 2 minutes to determine whether bradycardia and hemodynamic compromise persist. (AHA; Class I) 9
• Continuous rhythm monitoring is required, and mechanical capture must be verified by pulse or arterial waveform, not solely by ECG. (AHA; Class I) 9